Bayer HealthCare spin-out AiCuris raises EUR 55 million
Wuppertal – Bayer’s anti-infectives spin-out AiCuris has raised EUR 55 million in this year’s largest financing round of a German biotech company lead by the existing shareholders. The money will be used to push Aicuris clinical development, with particular focus on phase IIa drug candidate AIC246 against infections with the human cytomegalie virus. It will also support other projects, such as against Herpes simplex, HIV, Hepatitis B and C or multi-resistant bacteria. The main investor is the Santo Holding, the financing vehicle of Andreas and Thomas Strüngmann, former owners of the generics company Hexal. AiCuris announced that is also in talks with strategic partners interested in the in-license of Aicuris’ HCMV programme, comprising three further compounds beyond AIC246.